Ying Sun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5214092/publications.pdf

Version: 2024-02-01

350 papers	18,052 citations	24978 57 h-index	21474 114 g-index
362 all docs	362 docs citations	362 times ranked	13345 citing authors

#	Article	IF	Citations
1	Nasopharyngeal carcinoma. Lancet, The, 2019, 394, 64-80.	6.3	1,667
2	CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein and Cell, 2015, 6, 363-372.	4.8	929
3	Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1509-1520.	5.1	704
4	Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine, 2019, 381, 1124-1135.	13.9	573
5	How Does Intensity-Modulated Radiotherapy Versus Conventional Two-Dimensional Radiotherapy Influence the Treatment Results inÂNasopharyngeal Carcinoma Patients?. International Journal of Radiation Oncology Biology Physics, 2011, 80, 661-668.	0.4	567
6	Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncology, The, 2012, 13, 163-171.	5.1	468
7	Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ: British Medical Journal, 2018, 363, k4226.	2.4	362
8	Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncology, The, 2012, 13, 633-641.	5.1	274
9	Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Research, 2019, 79, 4612-4626.	0.4	250
10	Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up. European Journal of Cancer, 2015, 51, 2587-2595.	1.3	245
11	Re-Evaluation of 6th Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement Based on Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1326-1334.	0.4	236
12	Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. Clinical Cancer Research, 2019, 25, 4271-4279.	3.2	234
13	Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncology, The, 2018, 19, 382-393.	5.1	232
14	Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. Radiology, 2019, 291, 677-686.	3.6	221
15	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics, 2017, 7, 3585-3594.	4.6	214
16	Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Research, 2020, 30, 1024-1042.	5.7	182
17	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 840-859.	0.8	178
18	Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Longâ€term results of phase 3 randomized controlled trial. International Journal of Cancer, 2019, 145, 295-305.	2.3	168

#	Article	IF	Citations
19	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.4	156
20	An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2021, 27, 330-341.	3.2	148
21	How Does Magnetic Resonance Imaging Influence Staging According to AJCC Staging System for Nasopharyngeal Carcinoma Compared With Computed Tomography?. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1368-1377.	0.4	145
22	Progress report of a randomized trial comparing longâ€term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer, 2013, 119, 2230-2238.	2.0	144
23	Proposed modifications and incorporation of plasma Epsteinâ€Barr virus DNA improve the TNM staging system for Epsteinâ€Barr virusâ€related nasopharyngeal carcinoma. Cancer, 2019, 125, 79-89.	2.0	143
24	Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 913-919.	2.3	135
25	The N Staging System in Nasopharyngeal Carcinoma with Radiation Therapy Oncology Group Guidelines for Lymph Node Levels Based on Magnetic Resonance Imaging. Clinical Cancer Research, 2008, 14, 7497-7503.	3.2	131
26	Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clinical Cancer Research, 2018, 24, 1824-1833.	3.2	128
27	The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Communications, 2021, 41, 1195-1227.	3.7	128
28	Gramâ€Negative Periodontal Bacteria Induce the Activation of Tollâ€Like Receptors 2 and 4, and Cytokine Production in Human Periodontal Ligament Cells. Journal of Periodontology, 2010, 81, 1488-1496.	1.7	126
29	Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiotherapy and Oncology, 2014, 110, 390-397.	0.3	126
30	Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy. Chinese Journal of Cancer, 2016, 35, 103.	4.9	124
31	Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging. Cancer, 2008, 113, 347-354.	2.0	119
32	The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma. Cancer, 2009, 115, 680-688.	2.0	118
33	Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. European Journal of Cancer, 2017, 75, 150-158.	1.3	115
34	Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma?. Radiotherapy and Oncology, 2012, 104, 294-299.	0.3	114
35	The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, 862-869.	0.4	110
36	Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics, 2019, 9, 7648-7665.	4.6	106

#	Article	IF	Citations
37	The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiotherapy and Oncology, 2012, 104, 331-337.	0.3	104
38	Baseline Serum Lactate Dehydrogenase Levels for Patients Treated With Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: A Predictor of Poor Prognosis and Subsequent Liver Metastasis. International Journal of Radiation Oncology Biology Physics, 2012, 82, e359-e365.	0.4	100
39	The Pretreatment Albumin to Globulin Ratio Has Predictive Value for Long-Term Mortality in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e94473.	1.1	99
40	Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nature Communications, 2019, 10, 3941.	5.8	98
41	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet, The, 2021, 398, 303-313.	6.3	98
42	Extension of Local Disease in Nasopharyngeal Carcinoma Detected by Magnetic Resonance Imaging: Improvement of Clinical Target Volume Delineation. International Journal of Radiation Oncology Biology Physics, 2009, 75, 742-750.	0.4	95
43	Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chinese Journal of Cancer, 2012, 31, 579-587.	4.9	94
44	Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy. ACS Nano, 2016, 10, 11548-11560.	7.3	88
45	Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma: A multi-institution clinical study. Radiotherapy and Oncology, 2015, 115, 407-411.	0.3	81
46	Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 2864-2873.	1.9	80
47	Prognostic significance of tumorâ€infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: A largeâ€scale cohort study. International Journal of Cancer, 2018, 142, 2558-2566.	2.3	73
48	The evolution of nasopharyngeal carcinoma staging. British Journal of Radiology, 2019, 92, 20190244.	1.0	73
49	Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicine. Cancer Communications, 2021, 41, 1100-1115.	3.7	71
50	Chemoradiotherapy Versus Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: A Systemic Review and Meta-analysis of 2138 Patients. Journal of Cancer, 2017, 8, 287-297.	1.2	70
51	Efficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials. Journal of Cancer, 2015, 6, 883-892.	1.2	68
52	Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinoma. Journal of Translational Medicine, 2015, 13, 364.	1.8	67
53	Gold-caged copolymer nanoparticles as multimodal synergistic photodynamic/photothermal/chemotherapy platform against lethality androgen-resistant prostate cancer. Biomaterials, 2019, 212, 73-86.	5.7	66
54	WTAP-mediated m6A modification of lncRNA DIAPH1-AS1 enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis. Cell Death and Differentiation, 2022, 29, 1137-1151.	5.0	66

#	Article	IF	Citations
55	Proposed Lymph Node Staging System Using the International Consensus Guidelines for Lymph Node Levels Is Predictive for Nasopharyngeal Carcinoma Patients From Endemic Areas Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 249-256.	0.4	65
56	Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959). BMC Medicine, 2019, 17, 190.	2.3	64
57	Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 355-361.	0.4	64
58	Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy. Autophagy, 2017, 13, 1176-1190.	4.3	63
59	Long Noncoding RNA TINCR-Mediated Regulation of Acetyl-CoA Metabolism Promotes Nasopharyngeal Carcinoma Progression and Chemoresistance. Cancer Research, 2020, 80, 5174-5188.	0.4	63
60	The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Research and Treatment, 2021, 53, 339-354.	1.3	63
61	GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Theranostics, 2019, 9, 1047-1065.	4.6	62
62	Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up. Theranostics, 2017, 7, 2314-2324.	4.6	61
63	Prognostic Impact of Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Treated using Intensity-Modulated Radiation Therapy. Scientific Reports, 2016, 6, 22000.	1.6	58
64	10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma. Oncologist, 2019, 24, e38-e45.	1.9	57
65	Radiation-induced temporal lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a dose-volume-outcome analysis. BMC Cancer, 2013, 13, 397.	1.1	56
66	The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. Cancer Research and Treatment, 2018, 50, 19-29.	1.3	56
67	Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials, 2013, 34, 4068-4077.	5.7	54
68	MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2. Cancer Letters, 2015, 363, 146-155.	3.2	54
69	Development of targeted therapies in treatment of glioblastoma. Cancer Biology and Medicine, 2015, 12, 223-37.	1.4	54
70	Prognostic value of plasma Epsteinâ€“Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy. Chinese Journal of Cancer, 2017, 36, 87.	4.9	53
71	MicroRNA-125a-Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Restoring Effector/Regulatory T Cells Balance. ACS Nano, 2020, 14, 4414-4429.	7.3	53
72	The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Scientific Reports, 2016, 6, 24835.	1.6	52

#	Article	IF	Citations
73	EZH2-DNMT1-mediated epigenetic silencing of miR-142-3p promotes metastasis through targeting ZEB2 in nasopharyngeal carcinoma. Cell Death and Differentiation, 2019, 26, 1089-1106.	5.0	52
74	Prognostic Value and Staging Categories of Anatomic Masticator Space Involvement in Nasopharyngeal Carcinoma: A Study of 924 Cases with MR Imaging. Radiology, 2010, 257, 151-157.	3.6	51
75	Prognostic value of the primary lesion apparent diffusion coefficient (ADC) in nasopharyngeal carcinoma: a retrospective study of 541 cases. Scientific Reports, 2015, 5, 12242.	1.6	51
76	Multifunctional Shellâ€“Core Nanoparticles for Treatment of Multidrug Resistance Hepatocellular Carcinoma. Advanced Functional Materials, 2018, 28, 1706124.	7.8	51
77	Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial. Oncologist, 2016, 21, 1369-1376.	1.9	50
78	The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. Oncotarget, 2016, 7, 20890-20901.	0.8	49
79	Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma. EBioMedicine, 2019, 42, 270-280.	2.7	49
80	Exploration and Validation of C-Reactive Protein/Albumin Ratio as a Novel Inflammation-Based Prognostic Marker in Nasopharyngeal Carcinoma. Journal of Cancer, 2016, 7, 1406-1412.	1.2	48
81	Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy. Oral Oncology, 2017, 69, 99-107.	0.8	48
82	Tumor response to neoadjuvant chemotherapy predicts longâ€term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial. Cancer, 2017, 123, 1643-1652.	2.0	48
83	Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Molecular Cancer, 2021, 20, 14.	7.9	48
84	Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A largeâ€scale, bigâ€data intelligence platformâ€“based analysis from an endemic area. Cancer, 2017, 123, 3540-3549.	2.0	47
85	A Prognostic Predictive System Based on Deep Learning for Locoregionally Advanced Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2021, 113, 606-615.	3.0	47
86	Temperature-Sensitive Gold Nanoparticle-Coated Pluronic-PLL Nanoparticles for Drug Delivery and Chemo-Photothermal Therapy. Theranostics, 2017, 7, 4424-4444.	4.6	46
87	Genome-Wide Association Study of Susceptibility Loci for Radiation-Induced Brain Injury. Journal of the National Cancer Institute, 2019, 111, 620-628.	3.0	45
88	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncology, 2018, 4, 1073.	3.4	44
89	A deep survival analysis method based on ranking. Artificial Intelligence in Medicine, 2019, 98, 1-9.	3.8	44
90	Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2022, 40, 2420-2425.	0.8	44

#	Article	IF	Citations
91	Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in China. JAMA Oncology, 2022, 8, 1301.	3.4	44
92	Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget, 2016, 7, 24208-24216.	0.8	43
93	Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. Radiotherapy and Oncology, 2018, 129, 389-395.	0.3	43
94	Development and validation of an endoscopic imagesâ€based deep learning model for detection with nasopharyngeal malignancies. Cancer Communications, 2018, 38, 1-11.	3.7	43
95	Radiomics on multi-modalities MR sequences can subtype patients with non-metastatic nasopharyngeal carcinoma (NPC) into distinct survival subgroups. European Radiology, 2019, 29, 5590-5599.	2.3	43
96	Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncology, The, 2022, 23, 479-490.	5.1	43
97	Nano-ultrasonic Contrast Agent for Chemoimmunotherapy of Breast Cancer by Immune Metabolism Reprogramming and Tumor Autophagy. ACS Nano, 2022, 16, 3417-3431.	7.3	42
98	Prognostic Value of Subclassification Using MRI in the T4 Classification Nasopharyngeal Carcinoma Intensity-Modulated Radiotherapy Treatment. International Journal of Radiation Oncology Biology Physics, 2012, 84, 196-202.	0.4	41
99	YPEL3 suppresses epithelialâ€“mesenchymal transition and metastasis of nasopharyngeal carcinoma cells through the Wnt/Î²-catenin signaling pathway. Journal of Experimental and Clinical Cancer Research, 2016, 35, 109.	3.5	41
100	ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 11.	3.5	41
101	Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma. European Journal of Cancer, 2019, 110, 24-31.	1.3	40
102	Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. , 2019, 7, 298.		40
103	A New PAMPA Model Proposed on the Basis of a Synthetic Phospholipid Membrane. PLoS ONE, 2015, 10, e0116502.	1.1	40
104	Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. International Journal of Cancer, 2017, 141, 1265-1276.	2.3	38
105	Comparison of radiomics tools for image analyses and clinical prediction in nasopharyngeal carcinoma. British Journal of Radiology, 2019, 92, 20190271.	1.0	38
106	Assessment of Modifiable Factors for the Association of Marital Status With Cancer-Specific Survival. JAMA Network Open, 2021, 4, e2111813.	2.8	38
107	Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis. Oncotarget, 2015, 6, 29311-29323.	0.8	37
108	Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Oncotarget, 2016, 7, 6221-6230.	0.8	37

#	Article	IF	Citations
109	Prognostic value of chronic hepatitis B virus infection in patients with nasopharyngeal carcinoma: Analysis of 1301 patients from an endemic area in China. Cancer, 2014, 120, 68-76.	2.0	36
110	Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up. Journal of Cancer, 2017, 8, 455-459.	1.2	36
111	Toll-like receptor 4 signaling plays a role in triggering periodontal infection. FEMS Immunology and Medical Microbiology, 2008, 52, 362-369.	2.7	35
112	Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system. BMC Cancer, 2012, 12, 68.	1.1	35
113	Prognostic Value and Staging Classification of Retropharyngeal Lymph Node Metastasis in Nasopharyngeal Carcinoma Patients Treated with Intensity-modulated Radiotherapy. PLoS ONE, 2014, 9, e108375.	1.1	35
114	The Coexistence of SjÃ¶gren's Syndrome and Primary Biliary Cirrhosis: A Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2015, 48, 301-315.	2.9	35
115	Preparation of a Thermosensitive Gel Composed of a mPEG-PLGA-PLL-cRGD Nanodrug Delivery System for Pancreatic Tumor Therapy. ACS Applied Materials & Interfaces, 2015, 7, 20530-20537.	4.0	35
116	Hypermethylation of SHISA3 Promotes Nasopharyngeal Carcinoma Metastasis by Reducing SGSM1 Stability. Cancer Research, 2019, 79, 747-759.	0.4	35
117	Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma. Chinese Journal of Cancer, 2013, 32, 525-532.	4.9	35
118	Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. Scientific Reports, 2015, 5, 16664.	1.6	34
119	Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. Cancer Science, 2018, 109, 751-763.	1.7	34
120	Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma. Cancer, 2020, 126, 2163-2173.	2.0	34
121	Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance. Biomaterials, 2021, 269, 120478.	5.7	34
122	Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. Biomaterials, 2021, 275, 120988.	5.7	34
123	Low SFRP1 Expression Correlates with Poor Prognosis and Promotes Cell Invasion by Activating the Wnt/Î²-Catenin Signaling Pathway in NPC. Cancer Prevention Research, 2015, 8, 968-977.	0.7	33
124	Socioeconomic factors and survival in patients with nonâ€metastatic head and neck squamous cell carcinoma. Cancer Science, 2017, 108, 1253-1262.	1.7	33
125	Magnetic Resonance Imaging-Detected Tumor Residue after Intensity-Modulated Radiation Therapy and its Association with Post-Radiation Plasma Epstein-Barr Virus Deoxyribonucleic Acid in Nasopharyngeal Carcinoma. Journal of Cancer, 2017, 8, 861-869.	1.2	32
126	Clonal Mutations Activate the NF-ÎºB Pathway to Promote Recurrence of Nasopharyngeal Carcinoma. Cancer Research, 2019, 79, 5930-5943.	0.4	32

#	Article	IF	Citations
127	Unambiguous advanced radiologic extranodal extension determined by MRI predicts worse outcomes in nasopharyngeal carcinoma: Potential improvement for future editions of N category systems. Radiotherapy and Oncology, 2021, 157, 114-121.	0.3	32
128	Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e110765.	1.1	31
129	Delineation of Neck Clinical Target Volume Specific to Nasopharyngeal Carcinoma Based on Lymph Node Distribution and the International Consensus Guidelines. International Journal of Radiation Oncology Biology Physics, 2018, 100, 891-902.	0.4	31
130	A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry. Cancer Research and Treatment, 2018, 50, 324-334.	1.3	31
131	The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis. BMC Cancer, 2018, 18, 740.	1.1	31
132	Enhanced therapeutic effect of Adriamycin on multidrug resistant breast cancer by the ABCG2-siRNA loaded polymeric nanoparticles assisted with ultrasound. Oncotarget, 2015, 6, 43779-43790.	0.8	31
133	A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Nature Communications, 2022, 13, .	5.8	31
134	Grading of MRIâ€detected skullâ€base invasion in nasopharyngeal carcinoma and its prognostic value. Head and Neck, 2011, 33, 1309-1314.	0.9	30
135	Identification of miR-143 as a tumour suppressor in nasopharyngeal carcinoma based on microRNA expression profiling. International Journal of Biochemistry and Cell Biology, 2015, 61, 120-128.	1.2	30
136	Handgrip Strength Index Predicts Nutritional Status as a Complement to Body Mass Index in Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2016, 10, 1395-1400.	0.6	30
137	Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis. Oral Oncology, 2016, 62, 78-84.	0.8	30
138	Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis. Chinese Journal of Cancer, 2017, 36, 26.	4.9	30
139	5-Azacytidine Enhances the Radiosensitivity of CNE2 and SUNE1 Cells In Vitro and In Vivo Possibly by Altering DNA Methylation. PLoS ONE, 2014, 9, e93273.	1.1	30
140	Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysis. BMC Cancer, 2015, 15, 709.	1.1	29
141	Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?. Journal of Cancer, 2017, 8, 976-982.	1.2	29
142	Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epsteinâ€“Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma. Chinese Journal of Cancer, 2017, 36, 98.	4.9	29
143	Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a caseâ€“control study. BMC Cancer, 2017, 17, 567.	1.1	29
144	Nodal grouping in nasopharyngeal carcinoma: prognostic significance, N classification, and a marker for the identification of candidates for induction chemotherapy. European Radiology, 2020, 30, 2115-2124.	2.3	29

#	Article	IF	Citations
145	Genome-wide association study identifies genetic susceptibility loci and pathways of radiation-induced acute oral mucositis. Journal of Translational Medicine, 2020, 18, 224.	1.8	29
146	Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles. ACS Applied Materials & Interfaces, 2021, 13, 32763-32779.	4.0	29
147	Influence of Cervical Node Necrosis of Different Grades on the Prognosis of Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy. Journal of Cancer, 2017, 8, 959-966.	1.2	28
148	Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis. Oral Oncology, 2018, 79, 40-46.	0.8	28
149	The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy. Radiotherapy and Oncology, 2019, 131, 35-44.	0.3	28
150	Circulating EBV DNA, Globulin and Nodal Size Predict Distant Metastasis after Intensity-Modulated Radiotherapy in Stage II Nasopharyngeal Carcinoma. Journal of Cancer, 2016, 7, 664-670.	1.2	27
151	Is replacement of the supraclavicular fossa with the lower level classification based on magnetic resonance imaging beneficial in nasopharyngeal carcinoma?. Radiotherapy and Oncology, 2014, 113, 108-114.	0.3	26
152	Targeted polymeric therapeutic nanoparticles: Design and interactions with hepatocellular carcinoma. Biomaterials, 2015, 56, 229-240.	5.7	26
153	Impact of marital status at diagnosis on survival and its change over time between 1973 and 2012 in patients with nasopharyngeal carcinoma: a propensity scoreâ€matched analysis. Cancer Medicine, 2017, 6, 3040-3051.	1.3	26
154	A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy. Oral Oncology, 2017, 75, 89-94.	0.8	26
155	Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Radiotherapy and Oncology, 2019, 137, 137-144.	0.3	26
156	Panâ€cancer genomic analyses reveal prognostic and immunogenic features of the tumor melatonergic microenvironment across 14 solid cancer types. Journal of Pineal Research, 2019, 66, e12557.	3.4	26
157	Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. BMC Cancer, 2019, 19, 37.	1.1	26
158	Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy. Chinese Journal of Cancer, 2013, 32, 494-501.	4.9	26
159	Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy. Journal of Cancer, 2017, 8, 371-377.	1.2	25
160	Significant value of 18F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Chinese Journal of Cancer, 2017, 36, 95.	4.9	25
161	RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma. Clinical Cancer Research, 2018, 24, 6495-6508.	3.2	25
162	Prognostic value of retropharyngeal lymph node metastasis laterality in nasopharyngeal carcinoma and a proposed modification to the UICC/AJCC N staging system. Radiotherapy and Oncology, 2019, 140, 90-97.	0.3	25

#	Article	IF	Citations
163	Preparation of bufalin-loaded pluronic polyetherimide nanoparticles, cellular uptake, distribution, and effect on colorectal cancer. International Journal of Nanomedicine, 2014, 9, 4035.	3.3	24
164	Prognostic value of parapharyngeal extension in nasopharyngeal carcinoma treated with intensity modulated radiotherapy. Radiotherapy and Oncology, 2014, 110, 404-408.	0.3	24
165	Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy. BMC Cancer, 2015, 15, 810.	1.1	24
166	Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials. Radiotherapy and Oncology, 2015, 116, 157-166.	0.3	24
167	Prognostic implications of dynamic serum lactate dehydrogenase assessments in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Scientific Reports, 2016, 6, 22326.	1.6	24
168	Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Radiotherapy and Oncology, 2019, 132, 178-187.	0.3	24
169	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. Radiotherapy and Oncology, 2020, 151, 314-321.	0.3	24
170	Deep learning for risk prediction in patients with nasopharyngeal carcinoma using multi-parametric MRIs. Computer Methods and Programs in Biomedicine, 2020, 197, 105684.	2.6	24
171	Efficacy of Concurrent Chemotherapy for Intermediate Risk NPC in the Intensity-Modulated Radiotherapy Era: a Propensity-Matched Analysis. Scientific Reports, 2015, 5, 17378.	1.6	23
172	Degradation behavior and biosafety studies of the mPEGâ€“PLGAâ€“PLL copolymer. Physical Chemistry Chemical Physics, 2016, 18, 11986-11999.	1.3	23
173	Prognostic value of serum Epsteinâ€“Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epsteinâ€“Barr virus <scp>DNA</scp>. Cancer Science, 2017, 108, 1640-1647.	1.7	23
174	Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. Journal of Experimental and Clinical Cancer Research, 2017, 36, 147.	3.5	23
175	The Role of Post-Neoadjuvant Chemotherapy Tumor Volume for Prognostication and Treatment Guidance in Loco-Regionally Advanced Nasopharyngeal Carcinoma. Cancers, 2019, 11, 1632.	1.7	23
176	Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa. European Radiology, 2020, 30, 816-822.	2.3	23
177	An optimal posttreatment surveillance strategy for cancer survivors based on an individualized risk-based approach. Nature Communications, 2020, 11, 3872.	5.8	23
178	Role of Postoperative Radiotherapy in Nonmetastatic Head and Neck Adenoid Cystic Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1476-1484.	2.3	23
179	Nuclear overexpression of metastasis-associated protein 1 correlates significantly with poor survival in nasopharyngeal carcinoma. Journal of Translational Medicine, 2012, 10, 78.	1.8	22
180	The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy. Scientific Reports, 2016, 6, 24332.	1.6	22

#	Article	IF	Citations
181	Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A largeâ€scale cohort study. Cancer Science, 2018, 109, 1909-1919.	1.7	22
182	The prolonged interval between induction chemotherapy and radiotherapy is associated with poor prognosis in patients with nasopharyngeal carcinoma. Radiation Oncology, 2019, 14, 9.	1.2	22
183	Radiation Oncologistsâ€™ Perceptions of Adopting an Artificial Intelligenceâ€“Assisted Contouring Technology: Model Development and Questionnaire Study. Journal of Medical Internet Research, 2021, 23, e27122.	2.1	22
184	A Low-Producing Haplotype of Interleukin-6 Disrupting CTCF Binding Is Protective against Severe COVID-19. MBio, 2021, 12, e0137221.	1.8	22
185	Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Molecular Cancer, 2014, 13, 111.	7.9	21
186	The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC Cancer, 2015, 15, 977.	1.1	21
187	High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. BMC Cancer, 2015, 15, 332.	1.1	21
188	Publication status of contemporary oncology randomised controlled trials worldwide. European Journal of Cancer, 2016, 66, 17-25.	1.3	21
189	Pretreatment Nomograms for Local and Regional Recurrence after Radical Radiation Therapy for Primary Nasopharyngeal Carcinoma. Journal of Cancer, 2017, 8, 2595-2603.	1.2	21
190	The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database. PLoS ONE, 2018, 13, e0196730.	1.1	21
191	Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Communications, 2019, 39, 1-4.	3.7	21
192	Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensitymatched analysis. Oncotarget, 2016, 7, 14973-14982.	0.8	21
193	Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival. BMC Cancer, 2012, 12, 376.	1.1	20
194	Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities. PLoS ONE, 2015, 10, e0129679.	1.1	20
195	Combined prognostic value of pretreatment anemia and cervical node necrosis in patients with nasopharyngeal carcinoma receiving intensityâ€modulated radiotherapy: A largeâ€scale retrospective study. Cancer Medicine, 2017, 6, 2822-2831.	1.3	20
196	Role of sequential chemoradiotherapy in stage II and low-risk stage IIIâ€“IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis. Oral Oncology, 2018, 78, 37-45.	0.8	20
197	Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. Oral Oncology, 2018, 80, 1-8.	0.8	20
198	Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy. Oral Oncology, 2020, 107, 104675.	0.8	20

#	Article	IF	Citations
199	Treatment outcomes and feasibility of partial neck irradiation for patients with nasopharyngeal carcinoma with only retropharyngeal lymph node metastasis after intensityâ€modulated radiotherapy. Head and Neck, 2014, 36, 468-473.	0.9	19
200	Proposal of a Pretreatment Nomogram for Predicting Local Recurrence after Intensity-Modulated Radiation Therapy in T4 Nasopharyngeal Carcinoma: A Retrospective Review of 415 Chinese Patients. Cancer Research and Treatment, 2018, 50, 1084-1095.	1.3	19
201	Thyroid doseâ€volume thresholds for the risk of radiationâ€related hypothyroidism in nasopharyngeal carcinoma treated with intensityâ€modulated radiotherapyâ€"A singleâ€institution study. Cancer Medicine, 2019, 8, 6887-6893.	1.3	19
202	Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro. Oncotarget, 2016, 7, 80008-80018.	0.8	19
203	Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma. Oncotarget, 2015, 6, 13309-13319.	0.8	19
204	Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. Oncotarget, 2016, 7, 9576-9585.	0.8	19
205	ED ₅₀ and ED ₉₅ of propofol combined with different doses of esketamine for children undergoing upper gastrointestinal endoscopy: A prospective doseâ€finding study using upâ€andâ€down sequential allocation method. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1002-1009.	0.7	19
206	A polygenic risk score for nasopharyngeal carcinoma shows potential for risk stratification and personalized screening. Nature Communications, 2022, 13, 1966.	5.8	19
207	Altered Cell Cycle Arrest by Multifunctional Drug-Loaded Enzymatically-Triggered Nanoparticles. ACS Applied Materials & Interfaces, 2016, 8, 1360-1370.	4.0	18
208	Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. BMC Cancer, 2018, 18, 323.	1.1	18
209	Relationship between pretreatment concentration of plasma Epsteinâ€Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation. Cancer Medicine, 2018, 7, 5988-5998.	1.3	18
210	Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer Biology and Therapy, 2018, 19, 1102-1107.	1.5	18
211	NFAT1 Hypermethylation Promotes Epithelial-Mesenchymal Transition and Metastasis in Nasopharyngeal Carcinoma by Activating ITGA6 Transcription. Neoplasia, 2019, 21, 311-321.	2.3	18
212	Establishment of an integrated model incorporating standardised uptake value and N-classification for predicting metastasis in nasopharyngeal carcinoma. Oncotarget, 2016, 7, 13612-13620.	0.8	18
213	Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. Oncology Reports, 2014, 32, 1661-1669.	1.2	17
214	With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a caseâ€"control study. BMC Cancer, 2016, 16, 774.	1.1	17
215	Effects of sevoflurane on NF-ÐºB and TNF-Î± expression in renal ischemiaâ€"reperfusion diabetic rats. Inflammation Research, 2017, 66, 901-910.	1.6	17
216	Advances in nasopharyngeal carcinomaâ€"â€œWest meets Eastâ€. British Journal of Radiology, 2019, 92, 20199004.	1.0	17

#	Article	IF	Citations
217	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. Journal of the National Cancer Institute, 2021, 113, 471-480.	3.0	17
218	Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study. Neuro-Oncology, 2022, 24, 1559-1570.	0.6	17
219	Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma. Chinese Journal of Cancer, 2016, 35, 94.	4.9	16
220	The immune molecular landscape of the B7 and TNFR immunoregulatory ligandâ€“receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. OncoImmunology, 2017, 6, e1288329.	2.1	16
221	Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial. Radiotherapy and Oncology, 2018, 129, 18-22.	0.3	16
222	An integrated model of the gross tumor volume of cervical lymph nodes and pretreatment plasma Epsteinâ€“Barr virus DNA predicts survival of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987772.	1.4	16
223	Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification. Oral Oncology, 2019, 91, 7-12.	0.8	16
224	Subclassification of skull-base invasion for nasopharyngeal carcinoma using cluster, network and survival analyses: A double-center retrospective investigation. Radiotherapy and Oncology, 2019, 134, 37-43.	0.3	16
225	Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort. Oral Oncology, 2019, 89, 102-106.	0.8	16
226	Normal tissue complication probability (NTCP) models for predicting temporal lobe injury after intensity-modulated radiotherapy in nasopharyngeal carcinoma: A large registry-based retrospective study from China. Radiotherapy and Oncology, 2021, 157, 99-105.	0.3	16
227	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA â‰¥4000 copies/ml: a matched study. Oncotarget, 2016, 7, 29739-29748.	0.8	15
228	Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 336-344.	2.3	15
229	Development and implementation of a dynamically updated big data intelligence platform from electronic health records for nasopharyngeal carcinoma research. British Journal of Radiology, 2019, 92, 20190255.	1.0	15
230	Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Network Open, 2021, 4, e2110438.	2.8	15
231	The efficacy and toxicity of individualized intensity-modulated radiotherapy based on the tumor extension patterns of nasopharyngeal carcinoma. Oncotarget, 2016, 7, 20680-20690.	0.8	15
232	Ketosis Onset Type 2 Diabetes Had Better Islet<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi mathvariant="bold">Î²</mml:mi></mml:mrow></mml:math>-Cell Function and More Serious Insulin Resistance. Journal of Diabetes Research, 2014, 2014, 1-6.	1.0	14
233	Dose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma. Scientific Reports, 2015, 5, 13525.	1.6	14
234	Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiotherapy and Oncology, 2015, 116, 167-173.	0.3	14

#	Article	IF	Citations
235	Prognostic Value of Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma with Low Pre-treatment Epstein-Barr Virus DNA: a Propensity-matched Analysis. Journal of Cancer, 2016, 7, 1465-1471.	1.2	14
236	Magnetite loaded Polypeptideâ€PLGA multifunctional microbubbles for dualâ€mode US/MR imaging. Contrast Media and Molecular Imaging, 2016, 11, 146-153.	0.4	14
237	The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement. Oral Oncology, 2017, 69, 68-73.	0.8	14
238	Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis. Oral Oncology, 2020, 105, 104686.	0.8	14
239	An immuneâ€related sevenâ€lncRNA signature for head and neck squamous cell carcinoma. Cancer Medicine, 2021, 10, 2268-2285.	1.3	14
240	Enhanced delivery of PEAL nanoparticles with ultrasound targeted microbubble destruction mediated siRNA transfection in human MCF-7/S and MCF-7/ADR cells in vitro. International Journal of Nanomedicine, 2015, 10, 5447.	3.3	13
241	Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma. Oral Oncology, 2017, 73, 97-104.	0.8	13
242	Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. BMC Cancer, 2018, 18, 114.	1.1	13
243	Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual. Oral Oncology, 2019, 90, 23-29.	0.8	13
244	Establishing M1 stage subdivisions by incorporating radiological features and Epstein-Barr virus DNA for metastatic nasopharyngeal carcinoma. Annals of Translational Medicine, 2020, 8, 83-83.	0.7	13
245	The contrast-enhanced MRI can be substituted by unenhanced MRI in identifying and automatically segmenting primary nasopharyngeal carcinoma with the aid of deep learning models: An exploratory study in large-scale population of endemic area. Computer Methods and Programs in Biomedicine, 2022, 217, 106702.	2.6	13
246	Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy. Chinese Journal of Cancer, 2015, 34, 189-97.	4.9	12
247	CXCL12 genetic variants as prognostic markers in nasopharyngeal carcinoma. OncoTargets and Therapy, 2015, 8, 2835.	1.0	12
248	Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases. Journal of Cancer, 2016, 7, 1353-1359.	1.2	12
249	Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. Oral Oncology, 2017, 75, 120-126.	0.8	12
250	Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients. Journal of Cancer, 2017, 8, 1238-1248.	1.2	12
251	Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound. International Journal of Molecular Sciences, 2017, 18, 815.	1.8	12
252	Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. Radiotherapy and Oncology, 2021, 155, 56-64.	0.3	12

#	Article	IF	Citations
253	Brain-Specific Relative Biological Effectiveness of Protons Based on Long-term Outcome of Patients With Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 984-992.	0.4	12
254	Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area. Cancer Research and Treatment, 2021, 53, 657-670.	1.3	12
255	Which T Category of Nasopharyngeal Carcinoma May Benefit Most from Volumetric Modulated Arc Therapy Compared with Step and Shoot Intensity Modulated Radiation Therapy. PLoS ONE, 2013, 8, e75304.	1.1	12
256	A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. Oncotarget, 2016, 7, 21742-21752.	0.8	11
257	Advanced-Stage Nasopharyngeal Carcinoma: Restaging System after Neoadjuvant Chemotherapy on the Basis of MR Imaging Determines Survival. Radiology, 2017, 282, 171-181.	3.6	11
258	The Landscape of Clinical Trials Evaluating the Theranostic Role of PET Imaging in Oncology: Insights from an Analysis of ClinicalTrials.gov Database. Theranostics, 2017, 7, 390-399.	4.6	11
259	Antiâ€epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Cancer Science, 2018, 109, 1609-1616.	1.7	11
260	Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients. Radiation Oncology, 2018, 13, 141.	1.2	11
261	The development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensityâ€modulated radiotherapy era. Cancer Medicine, 2019, 8, 2213-2222.	1.3	11
262	Prognostic value of MRIâ€determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Medicine, 2020, 9, 7100-7106.	1.3	11
263	Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013. Cancer Research and Treatment, 2019, 51, 982-991.	1.3	11
264	Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma. Medical Oncology, 2013, 30, 360.	1.2	10
265	Refining the Role of Lymph Node Biopsy in Survival for Patients with Nasopharyngeal Carcinoma: Population-Based Study from the Surveillance Epidemiology and End-Results Registry. Annals of Surgical Oncology, 2017, 24, 2580-2587.	0.7	10
266	Prognostic value of cervical nodal tumor volume in nasopharyngeal carcinoma: Analysis of 1230 patients with positive cervical nodal metastasis. PLoS ONE, 2017, 12, e0176995.	1.1	10
267	Evolution and Dosimetric Analysis of Magnetic Resonance Imagingâ€“Detected Brain Stem Injury After Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 124-131.	0.4	10
268	Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983386.	1.4	10
269	Clinical Characteristics and Prognostic Factors of Early and Late Recurrence After Definitive Radiotherapy for Nasopharyngeal Carcinoma. Frontiers in Oncology, 2020, 10, 1469.	1.3	10
270	Precision Embolism: Biocompatible Temperatureâ€Sensitive Hydrogels as Novel Embolic Materials for Both Mainstream and Peripheral Vessels. Advanced Functional Materials, 2021, 31, 2011170.	7.8	10

#	Article	IF	Citations
271	The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer. Journal of Nanobiotechnology, 2021, 19, 165.	4.2	10
272	Reduction of clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensityâ€modulated radiotherapy. Head and Neck, 2016, 38, E468-72.	0.9	9
273	Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes. Chinese Journal of Cancer, 2017, 36, 32.	4.9	9
274	The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses. Journal of Cancer, 2018, 9, 4510-4520.	1.2	9
275	Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study. Oncotarget, 2016, 7, 16806-16817.	0.8	9
276	Magnetic polymeric nanobubbles with optimized core size for MRI/ultrasound bimodal molecular imaging of prostate cancer. Nanomedicine, 2020, 15, 2901-2916.	1.7	9
277	Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110524.	1.4	9
278	Treatment results and prognostic analysis of 1093 primary nasopharyngeal carcinoma: the experience of a single institution of Guangzhou in the beginning of the 21st century. Chinese-German Journal of Clinical Oncology, 2008, 7, 187-195.	0.1	8
279	The Evolution of and Risk Factors for Neck Muscle Atrophy and Weakness in Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy. Medicine (United States), 2015, 94, e1294.	0.4	8
280	Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma. Head and Neck, 2017, 39, 492-497.	0.9	8
281	Importance of maintaining body weight for prevention of distant metastasis of nasopharyngeal carcinoma: An alternative workflow for cancer-risk assessment. Journal of Cancer, 2017, 8, 2269-2276.	1.2	8
282	The prediction probabilities for emergence from sevoflurane anesthesia in children: A comparison of the perfusion index and the bispectral index. Paediatric Anaesthesia, 2018, 28, 281-286.	0.6	8
283	Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients With Nasopharyngeal Carcinoma After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1382-1391.	0.4	8
284	Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma. BMC Cancer, 2018, 18, 1276.	1.1	8
285	Prognostic value of serum bilirubin in southern Chinese patients with advanced nasopharyngeal carcinoma. Clinica Chimica Acta, 2018, 484, 314-319.	0.5	8
286	Nanoparticle BAF312@CaP-NP Overcomes Sphingosine-1-Phosphate Receptor-1-Mediated Chemoresistance Through Inhibiting S1PR1/P-STAT3 Axis in Ovarian Carcinoma . International Journal of Nanomedicine, 2020, Volume 15, 5561-5571.	3.3	8
287	Retropharyngeal Lymph Node Metastasis Diagnosed by Magnetic Resonance Imaging in Hypopharyngeal Carcinoma: A Retrospective Analysis From Chinese Multi-Center Data. Frontiers in Oncology, 2021, 11, 649540.	1.3	8
288	Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy. PLoS ONE, 2016, 11, e0161878.	1.1	8

#	Article	IF	Citations
289	Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area. Cancer Research and Treatment, 2018, 50, 777-790.	1.3	8
290	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiotherapy and Oncology, 2022, 167, 179-186.	0.3	8
291	Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Medicine, 2021, 19, 193.	2.3	8
292	Dose-volume relationships for moderate or severe neck muscle atrophy after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma. Scientific Reports, 2016, 5, 18415.	1.6	7
293	Nano Composite Thermo-Sensitive Gel for Paclitaxel and Temozolomide Co-Delivery to Glioblastoma Cells. Journal of Nanoscience and Nanotechnology, 2016, 16, 12288-12298.	0.9	7
294	Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy. Scientific Reports, 2016, 6, 22200.	1.6	7
295	Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 170-176.	0.4	7
296	Induction Chemotherapy Has No Prognostic Value in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Chronic Hepatitis B Infection in the IMRT Era. Translational Oncology, 2017, 10, 800-805.	1.7	7
297	Differential genome-wide profiling of alternative polyadenylation sites in nasopharyngeal carcinoma by high-throughput sequencing. Journal of Biomedical Science, 2018, 25, 74.	2.6	7
298	Evidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines. Oncologist, 2019, 24, 498-504.	1.9	7
299	Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China. Frontiers in Oncology, 2020, 10, 1572.	1.3	7
300	Development and validation of a webâ€based calculator to predict individualized conditional risk of siteâ€specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases. Cancer Communications, 2021, 41, 37-50.	3.7	7
301	Different Primary Sites of Hypopharyngeal Cancer Have Different Lymph Node Metastasis Patterns: A Retrospective Analysis From Multi-Center Data. Frontiers in Oncology, 2021, 11, 727991.	1.3	7
302	Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy. PLoS ONE, 2016, 11, e0166194.	1.1	7
303	Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. BMC Cancer, 2015, 15, 930.	1.1	6
304	The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA. Translational Oncology, 2017, 10, 527-534.	1.7	6
305	Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis. Journal of Cancer, 2017, 8, 2587-2594.	1.2	6
306	A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage IIâ€“IVa nasopharyngeal carcinoma. Oral Oncology, 2018, 86, 258-265.	0.8	6

#	Article	IF	Citations
307	Prognostic Value of Circulating Lipoprotein in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Cellular Physiology and Biochemistry, 2018, 48, 285-292.	1.1	6
308	Evaluation of the National Comprehensive Cancer Network and European Society for Medical Oncology Nasopharyngeal Carcinoma Surveillance Guidelines. Frontiers in Oncology, 2020, 10, 119.	1.3	6
309	Effect of recorded maternal voice on emergence agitation in children undergoing bilateral ophthalmic surgery: A randomised controlled trial. Journal of Paediatrics and Child Health, 2020, 56, 1402-1407.	0.4	6
310	Development of a Nomogram Model for Treatment of Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Journal of Personalized Medicine, 2021, 11, 1065.	1.1	6
311	Effects of advance exposure to an animated surgery-related picture book on preoperative anxiety and anesthesia induction in preschool children: a randomized controlled trial. BMC Pediatrics, 2022, 22, 92.	0.7	6
312	The Impact of Clinical Stage on Radiation Doses to Organs at Risk Following Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma: A Prospective Analysis. Journal of Cancer, 2016, 7, 2157-2164.	1.2	5
313	Evolving landscape and academic attitudes toward the controversies of global immunoâ€oncology trials. International Journal of Cancer, 2021, 149, 108-118.	2.3	5
314	Preemptive analgesic effectiveness of single dose intravenous ibuprofen in infants undergoing cleft palate repair: a randomized controlled trial. BMC Pediatrics, 2021, 21, 466.	0.7	5
315	Relationship between dioxins and steroid hormone in 6-year-olds: A follow-up study in an e-waste region of China. Chemosphere, 2022, 296, 134018.	4.2	5
316	Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0131284.	1.1	4
317	Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trial. Scientific Reports, 2015, 5, 12502.	1.6	4
318	Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis. Journal of Cancer, 2016, 7, 276-282.	1.2	4
319	Expression of prostaglandin E2 and EP receptors in human papillary thyroid carcinoma. Tumor Biology, 2016, 37, 4689-4697.	0.8	4
320	Prognostic value of primary gross tumor volume and standardized uptake value of 18F-FDG in PET/CT for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. Tumor Biology, 2017, 39, 101042831771784.	0.8	4
321	Dual-mode US/MRI nanoparticles delivering siRNA and Pt(<scp>iv</scp>) for ovarian cancer treatment. RSC Advances, 2019, 9, 33302-33309.	1.7	4
322	In-Air Electron Streaming Effect for Esophageal Cancer Radiotherapy With a 1.5 T Perpendicular Magnetic Field: A Treatment Planning Study. Frontiers in Oncology, 2020, 10, 607061.	1.3	4
323	Individualized elective irradiation of the clinically nodeâ€negative neck in definitive radiotherapy for head and neck squamous cell carcinoma. Cancer Communications, 2021, 41, 303-315.	3.7	4
324	Primary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patients. Oncotarget, 2016, 7, 14963-14972.	0.8	4

#	Article	IF	Citations
325	Prognostic effect of pregnancy on young female patients with nasopharyngeal carcinoma: results from a matched cohort analysis. Oncotarget, 2016, 7, 21913-21921.	0.8	4
326	Necrosis in a Biomarker-driven, Phase 2 Trial of Adjuvant Apatinib in Patients of Nasopharyngeal Carcinoma with Residual Epsteinâ€“Barr Virus DNA after Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	4
327	Study of SiRNA-loaded PS-mPEG/CaP nanospheres on lung cancer. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	3
328	Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncology, 2017, 3, 414.	3.4	3
329	The evolution of the nasopharyngeal carcinoma staging system over a 10-year period: implications for future revisions. Chinese Medical Journal, 2020, 133, 2044-2053.	0.9	3
330	Prognostic value of radiation interruption in different periods for nasopharyngeal carcinoma patients in the intensityâ€modulated radiation therapy era. Cancer Medicine, 2021, 10, 143-155.	1.3	3
331	The recovery of bladder epithelial hyperplasia caused by a melamine diet-induced bladder calculus in mice. Food and Chemical Toxicology, 2014, 64, 378-382.	1.8	2
332	The agreement between oscillometric and intraâ€arterial technique for blood pressure monitoring in the lower extremities for infants and toddlers undergoing aortic coarctation repair. Paediatric Anaesthesia, 2016, 26, 1091-1096.	0.6	2
333	Robust imaging and gene delivery to study human lymphoblastoid cell lines. Journal of Human Genetics, 2018, 63, 945-955.	1.1	2
334	Boron neutron capture therapy: moving towards targeted therapy for locally recurrent head and neck squamous cell carcinoma. Military Medical Research, 2019, 6, 32.	1.9	2
335	Association between outcome disparities and pragmatic features related to clinical trial and real-world settings in nasopharyngeal carcinoma: A population-based retrospective cohort study, 2006â€“2016. Radiotherapy and Oncology, 2020, 151, 306-313.	0.3	2
336	Effectiveness of postural lung recruitment on postoperative atelectasis assessed by lung ultrasound in children undergoing lateral thoracotomy cardiac surgery with cardiopulmonary bypass. Pediatric Pulmonology, 2021, 56, 1724-1732.	1.0	2
337	Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events. BMC Cancer, 2021, 21, 860.	1.1	2
338	CDCP1-targeted nanoparticles encapsulating phase-shift perfluorohexan for molecular US imaging in vitro. Clinical Hemorheology and Microcirculation, 2020, , 1-11.	0.9	2
339	Prognostic Value of Oral Epsteinâ€“Barr Virus DNA Load in Locoregionally Advanced Nasopharyngeal Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 757644.	1.6	2
340	Radiotherapy interruption due to holidays adversely affects the survival of patients with nasopharyngeal carcinoma: a joint analysis based on large-scale retrospective data and clinical trials. Radiation Oncology, 2022, 17, 36.	1.2	2
341	Intestinal Electric Stimulation Accelerates Whole Gut Transit and Promotes Fat Excrement in Conscious Rats. Nature Precedings, 2009, , .	0.1	1
342	Comparison of the ED50 propofol requirements during the insertion of laryngeal mask airway Ambu AuraFlex with Ambu AuraOnce in children undergoing strabismus surgery. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1629-1635.	0.7	1

#	Article	IF	Citations
343	Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA. BMC Medicine, 2021, 19, 193.	2.3	1
344	Differential benefit of induction chemotherapy according to body mass index in nasopharyngeal carcinoma â€“ Pooled analysis of two randomized trials. Oral Oncology, 2022, 125, 105718.	0.8	1
345	Transcriptomeâ€wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma. Cancer Communications, 2022, 42, 887-891.	3.7	1
346	Reply to Withington, Davinia, regarding their comment â€˜Comment on: Zâ€Z Peng â€œThe agreement between ocillometric and intraâ€arterial technique for blood pressure monitoring in the lower extremities of infants undergoing aortic coarctation repairâ€. Paediatric Anaesthesia, 2017, 27, 553-554.	0.6	0
347	Patient- and treatment-related risk factors associated with neck muscle spasm in nasopharyngeal carcinoma patients after intensity-modulated radiotherapy. BMC Cancer, 2017, 17, 788.	1.1	0
348	Serial Z-plasty for Correction of Cicatricial Conjunctival Constriction Rings. Journal of Craniofacial Surgery, 2019, 30, 1594-1596.	0.3	0
349	The role of artificial intelligence in nasopharyngeal carcinoma radiotherapy. Annals of Nasopharynx Cancer, 0, 4, 2-2.	0.5	0
350	Ultrasound-based nanomedicine for molecular imaging of prostate cancer: from diagnostics to theranostics. Nanomedicine, 2021, 16, 2029-2032.	1.7	0